ES2566011T3 - Péptido de epítopo HIG2 y URLC10 y vacunas que contienen el mismo - Google Patents
Péptido de epítopo HIG2 y URLC10 y vacunas que contienen el mismo Download PDFInfo
- Publication number
- ES2566011T3 ES2566011T3 ES09808048.4T ES09808048T ES2566011T3 ES 2566011 T3 ES2566011 T3 ES 2566011T3 ES 09808048 T ES09808048 T ES 09808048T ES 2566011 T3 ES2566011 T3 ES 2566011T3
- Authority
- ES
- Spain
- Prior art keywords
- hla
- present
- peptides
- peptide
- ctl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 99
- 101000839066 Homo sapiens Hypoxia-inducible lipid droplet-associated protein Proteins 0.000 title description 22
- 102100028891 Hypoxia-inducible lipid droplet-associated protein Human genes 0.000 title description 22
- 229960005486 vaccine Drugs 0.000 title description 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 59
- 206010028980 Neoplasm Diseases 0.000 abstract description 24
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 24
- 102000036639 antigens Human genes 0.000 abstract description 21
- 108091007433 antigens Proteins 0.000 abstract description 21
- 239000000427 antigen Substances 0.000 abstract description 20
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 18
- 201000011510 cancer Diseases 0.000 abstract description 16
- 230000006698 induction Effects 0.000 abstract description 15
- 238000011282 treatment Methods 0.000 abstract description 10
- 108010075704 HLA-A Antigens Proteins 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 230000002980 postoperative effect Effects 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 102000011786 HLA-A Antigens Human genes 0.000 abstract 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- 210000000612 antigen-presenting cell Anatomy 0.000 description 38
- 238000000034 method Methods 0.000 description 33
- 108091033319 polynucleotide Proteins 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 29
- 239000002157 polynucleotide Substances 0.000 description 29
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 210000001808 exosome Anatomy 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 6
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 6
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000008196 pharmacological composition Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 201000010174 renal carcinoma Diseases 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- -1 cationic lipid Chemical class 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8997208P | 2008-08-19 | 2008-08-19 | |
| US89972P | 2008-08-19 | ||
| PCT/JP2009/003897 WO2010021112A1 (en) | 2008-08-19 | 2009-08-14 | Hig2 and urlc10 epitope peptide and vaccines containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2566011T3 true ES2566011T3 (es) | 2016-04-08 |
Family
ID=41707003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09808048.4T Active ES2566011T3 (es) | 2008-08-19 | 2009-08-14 | Péptido de epítopo HIG2 y URLC10 y vacunas que contienen el mismo |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9119800B2 (enExample) |
| EP (1) | EP2328600B9 (enExample) |
| JP (1) | JP5633025B2 (enExample) |
| KR (1) | KR101713581B1 (enExample) |
| CN (2) | CN104958753B (enExample) |
| AU (1) | AU2009283763B2 (enExample) |
| BR (1) | BRPI0917391A2 (enExample) |
| CA (1) | CA2734467C (enExample) |
| DK (1) | DK2328600T3 (enExample) |
| ES (1) | ES2566011T3 (enExample) |
| IL (1) | IL211117A (enExample) |
| MX (2) | MX337756B (enExample) |
| RU (1) | RU2529373C2 (enExample) |
| SG (2) | SG10201610206VA (enExample) |
| TW (2) | TWI543767B (enExample) |
| WO (1) | WO2010021112A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI610939B (zh) * | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| SI2640842T1 (sl) * | 2010-11-17 | 2018-09-28 | Aduro Biotech, Inc. | Postopki in sestavki za induciranje imunskega odziva na EGFRvIII |
| JP6255594B2 (ja) | 2012-07-10 | 2018-01-10 | オンコセラピー・サイエンス株式会社 | Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン |
| US10576097B2 (en) * | 2014-08-04 | 2020-03-03 | Oncotherapy Science, Inc. | URLC10-derived peptide and vaccine containing same |
| RU2758112C2 (ru) | 2015-08-10 | 2021-10-26 | Торэй Индастриз, Инк. | Индуктор иммунитета |
| KR20180033585A (ko) | 2015-08-12 | 2018-04-03 | 온코세라피 사이언스 가부시키가이샤 | Depdc1-유래 펩티드 및 이를 포함하는 백신 |
| IL310182A (en) | 2017-04-26 | 2024-03-01 | Eureka Therapeutics Inc ׂ A Delaware Corp | Structures of chimeric antibody/T-cell receptor and uses thereof |
| PL3538645T3 (pl) | 2017-06-20 | 2021-11-08 | Institut Curie | Komórki odpornościowe z defektem suv39h1 |
| CN115300609A (zh) * | 2021-05-08 | 2022-11-08 | 西湖大学 | 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070014787A1 (en) | 1998-07-15 | 2007-01-18 | Human Genome Sciences, Inc. | 71 human secreted proteins |
| AU6318300A (en) * | 1999-08-05 | 2001-03-05 | Kyogo Itoh | Tumor antigen |
| WO2001023426A2 (en) | 1999-09-30 | 2001-04-05 | Varian Associates, Inc. | Hypoxia-related human genes, proteins, and uses thereof |
| JP2005506033A (ja) | 2000-10-13 | 2005-03-03 | イーオーエス バイオテクノロジー インコーポレイテッド | 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法 |
| US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20070015271A1 (en) | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2005019475A2 (en) * | 2003-08-20 | 2005-03-03 | Oncotherapy Science, Inc. | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) |
| CA2570392A1 (en) * | 2004-06-21 | 2005-12-29 | Green Peptide Co., Ltd. | Peptide vaccine for cancer therapy |
| CN101175862A (zh) | 2005-02-10 | 2008-05-07 | 肿瘤疗法科学股份有限公司 | 诊断膀胱癌的方法 |
| DK2325306T3 (en) | 2005-02-25 | 2014-03-03 | Oncotherapy Science Inc | Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide |
| CA2599875A1 (en) | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | Preventive/therapeutic agent for cancer |
| JP2009502112A (ja) | 2005-07-28 | 2009-01-29 | オンコセラピー・サイエンス株式会社 | 腎細胞癌を診断および処置するための方法 |
| JP5116150B2 (ja) * | 2005-09-07 | 2013-01-09 | 日本電気株式会社 | Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター |
| JP4840858B2 (ja) * | 2006-03-16 | 2011-12-21 | 学校法人慶應義塾 | 癌ワクチン |
| ATE509096T1 (de) | 2006-06-16 | 2011-05-15 | Onco Therapy Science Inc | Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält |
| TWI610939B (zh) | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| US20100291091A1 (en) | 2007-07-30 | 2010-11-18 | ONCOTHERAPY SCIENCE ,inc. | Cancer associated gene ly6k |
| TW201000115A (en) | 2008-06-11 | 2010-01-01 | Oncotherapy Science Inc | IQGAP3 epitope peptides and vaccines containing the same |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2009
- 2009-08-13 TW TW098127226A patent/TWI543767B/zh active
- 2009-08-13 TW TW103132024A patent/TWI580431B/zh not_active IP Right Cessation
- 2009-08-14 BR BRPI0917391A patent/BRPI0917391A2/pt not_active Application Discontinuation
- 2009-08-14 CA CA2734467A patent/CA2734467C/en active Active
- 2009-08-14 SG SG10201610206VA patent/SG10201610206VA/en unknown
- 2009-08-14 JP JP2011507735A patent/JP5633025B2/ja active Active
- 2009-08-14 DK DK09808048.4T patent/DK2328600T3/en active
- 2009-08-14 SG SG2013062690A patent/SG193806A1/en unknown
- 2009-08-14 EP EP09808048.4A patent/EP2328600B9/en active Active
- 2009-08-14 CN CN201510236002.5A patent/CN104958753B/zh active Active
- 2009-08-14 CN CN200980141320.6A patent/CN102186491B/zh active Active
- 2009-08-14 US US13/059,618 patent/US9119800B2/en active Active
- 2009-08-14 RU RU2011110376/10A patent/RU2529373C2/ru not_active IP Right Cessation
- 2009-08-14 KR KR1020117005809A patent/KR101713581B1/ko active Active
- 2009-08-14 WO PCT/JP2009/003897 patent/WO2010021112A1/en not_active Ceased
- 2009-08-14 AU AU2009283763A patent/AU2009283763B2/en not_active Ceased
- 2009-08-14 ES ES09808048.4T patent/ES2566011T3/es active Active
- 2009-08-14 MX MX2011001883A patent/MX337756B/es active IP Right Grant
- 2009-08-14 MX MX2013010331A patent/MX355054B/es unknown
-
2011
- 2011-02-08 IL IL211117A patent/IL211117A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2566011T3 (es) | Péptido de epítopo HIG2 y URLC10 y vacunas que contienen el mismo | |
| ES2415958T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos MPHOSPH1 ó DEPDC1 | |
| JP2022116237A (ja) | ネオ抗原およびその使用方法 | |
| RU2700929C2 (ru) | Пептидная вакцина, включающая пептид ras, содержащий мутации, и химиотерапевтический агент | |
| ES2459492T3 (es) | Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1 | |
| ES2618896T3 (es) | Péptidos de FOXM1 y vacunas que contienen los mismos | |
| TW201008574A (en) | INHBB epitope peptides and vaccines containing the same | |
| TW200906850A (en) | TEM8 peptides and vaccines comprising the same | |
| Fang et al. | The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model | |
| TWI441648B (zh) | Ｆｏｘｐ３胜肽疫苗 | |
| MX2010013680A (es) | Peptidos del epitope iqgap3 y vacunas que los contienen. | |
| JP2012102105A (ja) | 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン | |
| TW201000119A (en) | MYBL2 epitope peptides and vaccines containing the same | |
| JP5435938B2 (ja) | ワクチン接種のための天然ペプチド及びそれらの最適化された誘導体の使用 | |
| ES2631952T3 (es) | Péptidos CDC45L y vacunas que incluyen los mismos | |
| ES2541325T3 (es) | Péptido de epítopo RAB6KIFL/KIF20A y vacunas que contienen el mismo | |
| ES2655437T3 (es) | Péptidos de ECT2 y vacunas que incluyen los mismos | |
| WO2005061538A2 (en) | Vaccine comprising an angiomotin or a polynucleotide encoding an angiomotin and its uses for the treatment of angiogenic-related disorders | |
| RU2773273C2 (ru) | Неоантигены и способы их использования | |
| HK1152873B (en) | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |